UM

Browse/Search Results:  1-10 of 10 Help

Selected(0)Clear Items/Page:    Sort:
Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models Journal article
Guo, Yizhen, Lu, Xianchen, Zhou, Yan, Chen, Wen Hua, Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models[J]. Experimental Cell Research, 2023, 433(2), 113830.
Authors:  Guo, Yizhen;  Lu, Xianchen;  Zhou, Yan;  Chen, Wen Hua;  Tam, Kin Yip
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.3/3.3 | Submit date:2024/01/02
Cancer Metabolism  Combination Therapy  Hk2  Nsclc  Pdk1  
Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing Journal article
Zhou, Yan, Guo, Yizhen, Ran, Maoxin, Shan, Wenying, Granchi, Carlotta, Giovannetti, Elisa, Minutolo, Filippo, Peters, Godefridus J., Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing[J]. Cancer Letters, 2023, 577, 216425.
Authors:  Zhou, Yan;  Guo, Yizhen;  Ran, Maoxin;  Shan, Wenying;  Granchi, Carlotta; et al.
Favorite | TC[WOS]:9 TC[Scopus]:7  IF:9.1/8.3 | Submit date:2023/12/04
Anticancer  Combination Treatment  Non-small Cell Lung Cancer  Warburg Effect  
Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis Journal article
Zhou, Yan, Huang, Shiqi, Guo, Yizhen, Ran, Maxoin, Shan, Wenying, Wen-Hau Chen, Tam, Kin Yip. Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis[J]. Phytotheraphy Research, 2023, 37(12), 5837-5853.
Authors:  Zhou, Yan;  Huang, Shiqi;  Guo, Yizhen;  Ran, Maxoin;  Shan, Wenying; et al.
Favorite | TC[WOS]:6 TC[Scopus]:7  IF:6.1/7.0 | Submit date:2023/08/22
Acquired Drug Resistance  Combination Therapy  Egcg  Egfr-tkis  Nsclc  Synergetic Effect  
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models Journal article
Guo, Yizhen, Zhou, Yan, Wu, Puhua, Ran, Maoxin, Xu, Ngai, Shan, Wenying, Sha, Ou, Tam, Kin Yip. Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models[J]. Chemico-Biological Interactions, 2023, 378, 110467.
Authors:  Guo, Yizhen;  Zhou, Yan;  Wu, Puhua;  Ran, Maoxin;  Xu, Ngai; et al.
Favorite | TC[WOS]:5 TC[Scopus]:5  IF:4.7/4.6 | Submit date:2023/07/19
Anticancer Effect  Dichloroacetophenone  Metabolic Alteration  Nsclc  Pdk  
Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance Journal article
Ran,Maoxin, Zhou,Yan, Guo,Yizhen, Huang,Ding, Zhang,Shao Lin, Tam,Kin Yip. Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance[J]. FEBS Journal, 2023, 290(19), 4593-4810.
Authors:  Ran,Maoxin;  Zhou,Yan;  Guo,Yizhen;  Huang,Ding;  Zhang,Shao Lin; et al.
Favorite | TC[WOS]:3 TC[Scopus]:3  IF:5.5/5.5 | Submit date:2023/08/03
Acquired Drug Resistance  Glucose-6-phosphate Dehydrogenase  Malic Enzyme 1  Non-small-cell Lung Cancer  Redox Homeostasis  
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents Review article
2022
Authors:  Zhou, Yan;  Guo, Yizhen;  Tam, Kin Yip
Favorite | TC[WOS]:22 TC[Scopus]:21  IF:5.4/6.4 | Submit date:2022/05/17
Cancer Glucose Metabolism  Cancer Treatment Patent  Glycolytic Inhibitor  Hexokinase 2 (Hk2)  Lactate Dehydrogenase a (Ldha)  Pyruvate Dehydrogenase Kinase (Pdk)  Warburg Effect  
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents Journal article
Zhou Yan, Guo Yizhen, TAM KIN YIP. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2022, 32(4), 441-453.
Authors:  Zhou Yan;  Guo Yizhen;  TAM KIN YIP
Adobe PDF | Favorite | TC[WOS]:22 TC[Scopus]:21  IF:5.4/6.4 | Submit date:2024/08/29
Cancer Treatment Patent  Cancer Glucose Metabolism  Warburg Effect  Hexokinase 2 (Hk2)  Pyruvate Dehydrogenase Kinase (Pdk)  Lactate Dehydrogenase a (Ldha)  Glycolytic Inhibitor  
Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents Review article
2021
Authors:  Wu,Puhua;  Zhou,Yan;  Guo,Yizhen;  Zhang,Shao Lin;  Tam,Kin Yip
Favorite | TC[WOS]:14 TC[Scopus]:13  IF:6.5/7.3 | Submit date:2021/03/04
Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents Journal article
Wu Pahau, Zhou Yan, Guo Yizhen, Shaolin Zhang, TAM KIN YIP. Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents[J]. Drug Discovery Today, 2021, 26(3), 836-844.
Authors:  Wu Pahau;  Zhou Yan;  Guo Yizhen;  Shaolin Zhang;  TAM KIN YIP
Adobe PDF | Favorite | TC[WOS]:14 TC[Scopus]:13  IF:6.5/7.3 | Submit date:2024/08/29
Antineoplastic Agents  Drug Design  Drug Development  Glucose/metabolism  Glycolysis  Humans Monocarboxylic Acid Transporters  
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 Other
2016-01-01
Authors:  Klionsky, Daniel J.;  Abdelmohsen, Kotb;  Abe, Akihisa;  Abedin, Md Joynal;  Abeliovich, Hagai; et al.
Favorite | TC[WOS]:407 TC[Scopus]:24 | Submit date:2022/07/20